Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism

    Summary
    EudraCT number
    		 2020-003380-26
    Trial protocol
    		 DK   NO   FR   DE   HU   IT  
    Global end of trial date
    21 Jan 2025

    Results information
    Results version number
    		 v2(current)
    This version publication date
    06 Feb 2026
    First version publication date
    27 Apr 2023
    Other versions
    		 v1
    Version creation reason
    • New data added to full data set
    Update to include OLE safety data.

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    TCP-304
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT04701203
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Ascendis Pharma Bone Diseases A/S
    Sponsor organisation address
    Tuborg Boulevard 12, Hellerup, Denmark, DK 2900
    Public contact
    Clinical Trial Information Desk , Ascendis Pharma Bone Diseases A/S, 45 70222244, clinhelpdesk@ascendispharma.com
    Scientific contact
    Clinical Trial Information Desk , Ascendis Pharma Bone Diseases A/S, 45 70222244, clinhelpdesk@ascendispharma.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Oct 2025
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    21 Jan 2025
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the treatment effect of daily TransCon PTH on serum calcium levels, and therapeutic doses of active vitamin D (i.e., calcitriol or alfacalcidol) and calcium at 26 weeks of treatment.
    Protection of trial subjects
    Written informed consent was obtained from all subjects prior to enrollment into the trial, as dictated by the Declaration of Helsinki.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    28 Dec 2020
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Safety, Efficacy
    Long term follow-up duration
    		 3 Years
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 30
    Country: Number of subjects enrolled
    Canada: 21
    Country: Number of subjects enrolled
    Norway: 1
    Country: Number of subjects enrolled
    Denmark: 11
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    Hungary: 7
    Country: Number of subjects enrolled
    Italy: 11
    Worldwide total number of subjects
    82
    EEA total number of subjects
    31
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    72
    From 65 to 84 years
    10
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Overall, 82 subjects were enrolled and dosed. Enrollment of subjects occurred in seven countries: Canada, Denmark, Germany, Italy, Hungary, Norway, and the United States.

    Pre-assignment
    Screening details
    		 A total of 106 subjects were screened and 84 of these met eligibility criteria and were enrolled into the study. Two subjects randomised to TransCon PTH were not treated. A total of 82 subjects were therefore included in the ITT and the Safety analysis populations.

    Period 1
    Period 1 title
    Blinded Treatment Period (Weeks 0 to 26)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Data analyst, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Double Blind: TransCon PTH
    Arm description
    		 TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection and titrated to an optimal dose.
    Arm type
    		 Experimental

    Investigational medicinal product name
    TransCon PTH
    Investigational medicinal product code
    ACP-014
    Other name
    Palopegteriparatide
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    TransCon PTH drug product was supplied as a clear solution containing palopegteriparatide with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection. All subjects were initially prescribed TransCon PTH 18 μg PTH(1-34)/d and were individually and progressively titrated to an optimal dose (allowable range 6–60 μg/d) in increments of 3 μg/d. Titration of study drug and conventional therapy was performed according to a protocol-specified algorithm guided by serum calcium values.

    Arm title
    		 Double Blind: Placebo
    Arm description
    		 Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo for TransCon PTH drug product was supplied as a clear solution containing placebo liquid to match the investigational product in a pre-filled pen intended for subcutaneous injection.

    Number of subjects in period 1
    		Double Blind: TransCon PTH Double Blind: Placebo
    Started
    61
    21
    Completed
    60
    19
    Not completed
    1
    2
         Adverse event, serious fatal
    1
    -
         Consent withdrawn by subject
    -
    1
         Adverse event, non-fatal
    -
    1
    Period 2
    Period 2 title
    Open-Label Period (Weeks 26 to 182)
    Is this the baseline period?
    		 No
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 Open-Label Extension Period: TransCon PTH
    Arm description
    		 Subjects who completed the 26-week double treatment period, continued into the open-label extension period and received treatment with TransCon PTH up to Week 182. All participants received individualized doses of TransCon PTH (allowable dose range: 6 to 60 mcg/day).
    Arm type
    		 Experimental

    Investigational medicinal product name
    TransCon PTH
    Investigational medicinal product code
    ACP-014
    Other name
    Palopegteriparatide
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    TransCon PTH drug product was supplied as a clear solution containing palopegteriparatide with a nominal PTH (1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection. All subjects received individualized doses of TransCon PTH (allowable dose range: 6 to 60 µg/day).

    Number of subjects in period 2
    		Open-Label Extension Period: TransCon PTH
    Started
    79
    Completed
    73
    Not completed
    6
         Consent withdrawn by subject
    5
         Pregnancy
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Double Blind: TransCon PTH
    Reporting group description
    		 TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection and titrated to an optimal dose.

    Reporting group title
    Double Blind: Placebo
    Reporting group description
    		 Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product.

    Reporting group values
    		 Double Blind: TransCon PTH Double Blind: Placebo Total
    Number of subjects
    		 61 21 82
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 49.0 ( 13.13 ) 47.3 ( 11.43 ) -
    Gender categorical
    Units: Subjects
        Female
    		 46 18 64
        Male
    		 15 3 18
    Race
    Units: Subjects
        Asian
    		 3 2 5
        White
    		 57 19 76
        Other
    		 1 0 1
    Ethnicity
    Units: Subjects
        Not Hispanic or Latino
    		 57 18 75
        Not Reported
    		 3 1 4
        Unknown
    		 1 2 3
    Height
    Units: cm
        arithmetic mean (standard deviation)
    		 168.22 ( 8.353 ) 166.67 ( 8.831 ) -
    Weight
    Units: kg
        arithmetic mean (standard deviation)
    		 77.18 ( 17.335 ) 81.61 ( 15.631 ) -
    Body Mass Index
    Units: kg/m^2
        arithmetic mean (standard deviation)
    		 27.27 ( 5.813 ) 29.47 ( 5.691 ) -

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Double Blind: TransCon PTH
    Reporting group description
    		 TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection and titrated to an optimal dose.

    Reporting group title
    Double Blind: Placebo
    Reporting group description
    		 Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product.
    Reporting group title
    Open-Label Extension Period: TransCon PTH
    Reporting group description
    		 Subjects who completed the 26-week double treatment period, continued into the open-label extension period and received treatment with TransCon PTH up to Week 182. All participants received individualized doses of TransCon PTH (allowable dose range: 6 to 60 mcg/day).

    Primary: Efficacy - Primary Endpoint During the Blinded Period

    		 Close Top of page
    End point title
    		 Efficacy - Primary Endpoint During the Blinded Period
    End point description
    The primary endpoint was a multi-component endpoint that included the percentage of subjects who met the following criteria at 26 weeks of blinded treatment: 1) albumin-adjusted serum calcium measured within 4 weeks prior to and on Week 26 visit within the normal range (8.3 to 10.6 mg/dL), and 2) independence from active vitamin D within 4 weeks prior to Week 26 visit (i.e., all daily standing dose of active vitamin D equal to zero AND use of PRN ≤7 days during the 4 weeks), and 3) independence from therapeutic doses of calcium within 4 weeks prior to Week 26 visit (i.e., average daily standing dose of elemental calcium ≤600 mg AND use of PRN doses on ≤7 days during the 4 weeks) and, 4) no increase in prescribed study drug within 4 weeks prior to Week 26 visit.
    End point type
    Primary
    End point timeframe
    26 weeks
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    61
    21
    Units: Percentage of subjects
        number (confidence interval 95%)
    78.7 (66.3 to 88.1)
    4.8 (0.1 to 23.8)
    Statistical analysis title
    		 Primary efficacy endpoint
    Statistical analysis description
    For the primary efficacy endpoint, the Cochran–Mantel Haenszel test stratified by etiology of hypoparathyroidism (postsurgical or other) was used to compare the proportion of participants meeting the multi-component primary endpoint in the TransCon PTH versus placebo groups. Participants without week 26 albumin-adjusted serum calcium or with >25% (ie, >7 days) missing diary data of active vitamin D or elemental calcium during the 4 weeks before week 26 were considered non-responders.
    Comparison groups
    Double Blind: TransCon PTH v Double Blind: Placebo
    Number of subjects included in analysis
    82
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: Change From Baseline to Week 26 in HPES Symptom - Physical Domain Score

    		 Close Top of page
    End point title
    		 Change From Baseline to Week 26 in HPES Symptom - Physical Domain Score
    End point description
    Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Physical Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related physical symptoms.
    End point type
    Secondary
    End point timeframe
    Week 26
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    59
    19
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -21.01 (-25.41 to -16.60)
    -4.81 (-15.22 to 5.59)
    Statistical analysis title
    		 HPES - Symptom - Physical Domain Score
    Statistical analysis description
    ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
    Comparison groups
    Double Blind: TransCon PTH v Double Blind: Placebo
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 equivalence
    P-value
    		 = 0.0038
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: Change From Baseline to Week 26 in HPES Symptom - Cognitive Domain Score

    		 Close Top of page
    End point title
    		 Change From Baseline to Week 26 in HPES Symptom - Cognitive Domain Score
    End point description
    Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Cognitive Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related cognitive symptoms.
    End point type
    Secondary
    End point timeframe
    Week 26
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    59
    19
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -20.49 (-25.67 to -15.31)
    -6.16 (-15.92 to 3.60)
    Statistical analysis title
    		 HPES - Symptom - Cognitive Domain Score
    Statistical analysis description
    ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
    Comparison groups
    Double Blind: Placebo v Double Blind: TransCon PTH
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 equivalence
    P-value
    		 = 0.0055
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: Change From Baseline to Week 26 in HPES Impact - Physical Functioning Domain Score

    		 Close Top of page
    End point title
    		 Change From Baseline to Week 26 in HPES Impact - Physical Functioning Domain Score
    End point description
    Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Physical Functioning Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in physical functioning health-related quality of life.
    End point type
    Secondary
    End point timeframe
    Week 26
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    59
    19
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -18.29 (-23.59 to -12.99)
    -1.01 (-12.40 to 10.38)
    Statistical analysis title
    		 HPES - Impact - Physical Functioning Domain Score
    Statistical analysis description
    ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
    Comparison groups
    Double Blind: TransCon PTH v Double Blind: Placebo
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 equivalence
    P-value
    		 = 0.0046
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: Change From Baseline to Week 26 in HPES Impact - Daily Life Domain Score

    		 Close Top of page
    End point title
    		 Change From Baseline to Week 26 in HPES Impact - Daily Life Domain Score
    End point description
    Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Daily Life Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in daily health-related quality of life.
    End point type
    Secondary
    End point timeframe
    Week 26
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    59
    19
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -17.65 (-22.39 to -12.91)
    -0.36 (-12.19 to 11.46)
    Statistical analysis title
    		 HPES - Impact - Daily Life Domain Score
    Statistical analysis description
    ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
    Comparison groups
    Double Blind: TransCon PTH v Double Blind: Placebo
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 equivalence
    P-value
    		 = 0.0061
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: Change From Baseline to Week 26 in SF-36 Physical Functioning Subscale Score

    		 Close Top of page
    End point title
    		 Change From Baseline to Week 26 in SF-36 Physical Functioning Subscale Score
    End point description
    Change from baseline in the 36-item Short Form Survey (SF-36) Physical Functioning subscale score, a generic health survey, at 26 weeks of treatment. The Physical Functioning subscale uses a range of 19-57.6 and values represent the change in scores from baseline. An increase in SF-36 score denotes an improvement in physical functioning health-related quality of life.
    End point type
    Secondary
    End point timeframe
    Week 26
    End point values
    		 Double Blind: TransCon PTH Double Blind: Placebo
    Number of subjects analysed
    59
    19
    Units: units on a scale
        least squares mean (confidence interval 95%)
    5.29 (3.47 to 7.10)
    0.12 (-4.64 to 4.89)
    Statistical analysis title
    		 SF-36 – Physical Functioning Subscale Score
    Statistical analysis description
    ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
    Comparison groups
    Double Blind: TransCon PTH v Double Blind: Placebo
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 equivalence
    P-value
    		 = 0.0347
    Method
    		 t-test, 2-sided
    Confidence interval

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Week 0 to Week 26 for double-blind treatment period and up to Week 182 for open label extension (OLE) period
    Adverse event reporting additional description
    Analysed on safety analysis set that included all randomised subjects who received at least one dose of trial drug and were analysed according to actual study treatment received.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Double Blind: TransCon PTH
    Reporting group description
    		 TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection and titrated to an optimal dose during the blinded period.

    Reporting group title
    Double Blind: Placebo
    Reporting group description
    		 Placebo for TransCon PTH delivered once daily by subcutaneous injection during the blinded period.

    Reporting group title
    Total TransCon PTH Period
    Reporting group description
    		 Subjects who completed the 26-week double blind treatment period in placebo and TransCon PTH groups, continued into the open-label extension (OLE) period and received treatment with TransCon PTH up to Week 182. This period refers to total period of exposure to TransCon PTH. For subjects randomised to TransCon PTH at enrollment, the "TransCon PTH Period" was the time from first dose of blinded TransCon PTH until final analysis in OLE period. The TransCon PTH Period for subjects randomised to placebo at enrollment was the time from first exposure to TransCon PTH at the time of cross-over from placebo, until final analysis in the OLE.

    Serious adverse events
    		 Double Blind: TransCon PTH Double Blind: Placebo Total TransCon PTH Period
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 61 (8.20%)
    2 / 21 (9.52%)
    20 / 80 (25.00%)
         number of deaths (all causes)
    1
    0
    1
         number of deaths resulting from adverse events
    1
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Invasive breast carcinoma
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 21 (4.76%)
    0 / 80 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tongue neoplasm malignant stage unspecified
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Hypertensive crisis
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac arrest
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    Cardiac failure
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Deafness neurosensory
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    2 / 80 (2.50%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Proctalgia
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Endometrial disorder
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Bipolar disorder
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 21 (4.76%)
    0 / 80 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post-traumatic stress disorder
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Neck pain
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    2 / 80 (2.50%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Enteritis infectious
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Skin infection
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    1 / 80 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypercalcaemia
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    2 / 80 (2.50%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypocalcaemia
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Double Blind: TransCon PTH Double Blind: Placebo Total TransCon PTH Period
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    50 / 61 (81.97%)
    20 / 21 (95.24%)
    72 / 80 (90.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    3 / 61 (4.92%)
    3 / 21 (14.29%)
    12 / 80 (15.00%)
         occurrences all number
    3
    3
    13
    Orthostatic hypotension
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    10 / 80 (12.50%)
         occurrences all number
    1
    0
    12
    General disorders and administration site conditions
    Injection site reaction
         subjects affected / exposed
    19 / 61 (31.15%)
    0 / 21 (0.00%)
    20 / 80 (25.00%)
         occurrences all number
    20
    0
    22
    Fatigue
         subjects affected / exposed
    9 / 61 (14.75%)
    5 / 21 (23.81%)
    18 / 80 (22.50%)
         occurrences all number
    10
    5
    23
    Asthenia
         subjects affected / exposed
    3 / 61 (4.92%)
    1 / 21 (4.76%)
    6 / 80 (7.50%)
         occurrences all number
    3
    1
    6
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    1
    0
    4
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal pain
         subjects affected / exposed
    4 / 61 (6.56%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    4
    0
    5
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    4 / 61 (6.56%)
    1 / 21 (4.76%)
    7 / 80 (8.75%)
         occurrences all number
    4
    1
    7
    Investigations
    Blood thyroid stimulating hormone decreased
         subjects affected / exposed
    3 / 61 (4.92%)
    3 / 21 (14.29%)
    11 / 80 (13.75%)
         occurrences all number
    3
    3
    11
    Blood thyroid stimulating hormone increased
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    8 / 80 (10.00%)
         occurrences all number
    1
    0
    15
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    3 / 61 (4.92%)
    1 / 21 (4.76%)
    5 / 80 (6.25%)
         occurrences all number
    5
    1
    9
    Medication error
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    3
    0
    5
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    9 / 80 (11.25%)
         occurrences all number
    4
    0
    11
    Postural orthostatic tachycardia syndrome
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    7 / 80 (8.75%)
         occurrences all number
    2
    0
    9
    Nervous system disorders
    Headache
         subjects affected / exposed
    13 / 61 (21.31%)
    2 / 21 (9.52%)
    19 / 80 (23.75%)
         occurrences all number
    20
    2
    28
    Paraesthesia
         subjects affected / exposed
    12 / 61 (19.67%)
    3 / 21 (14.29%)
    21 / 80 (26.25%)
         occurrences all number
    19
    10
    34
    Dizziness
         subjects affected / exposed
    4 / 61 (6.56%)
    0 / 21 (0.00%)
    7 / 80 (8.75%)
         occurrences all number
    4
    0
    9
    Brain fog
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 21 (4.76%)
    6 / 80 (7.50%)
         occurrences all number
    1
    1
    7
    Dizziness postural
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    3
    0
    4
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    7 / 61 (11.48%)
    2 / 21 (9.52%)
    12 / 80 (15.00%)
         occurrences all number
    11
    3
    19
    Diarrhoea
         subjects affected / exposed
    6 / 61 (9.84%)
    1 / 21 (4.76%)
    7 / 80 (8.75%)
         occurrences all number
    6
    1
    12
    Constipation
         subjects affected / exposed
    4 / 61 (6.56%)
    1 / 21 (4.76%)
    5 / 80 (6.25%)
         occurrences all number
    5
    1
    8
    Vomiting
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    6
    0
    9
    Dry mouth
         subjects affected / exposed
    2 / 61 (3.28%)
    1 / 21 (4.76%)
    5 / 80 (6.25%)
         occurrences all number
    2
    1
    5
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    0
    0
    5
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    1
    0
    5
    Alopecia
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    2
    0
    4
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 21 (4.76%)
    4 / 80 (5.00%)
         occurrences all number
    0
    1
    4
    Pollakiuria
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    3
    0
    4
    Musculoskeletal and connective tissue disorders
    Muscle spasms
         subjects affected / exposed
    7 / 61 (11.48%)
    3 / 21 (14.29%)
    17 / 80 (21.25%)
         occurrences all number
    7
    3
    23
    Arthralgia
         subjects affected / exposed
    6 / 61 (9.84%)
    2 / 21 (9.52%)
    13 / 80 (16.25%)
         occurrences all number
    7
    2
    17
    Myalgia
         subjects affected / exposed
    3 / 61 (4.92%)
    1 / 21 (4.76%)
    8 / 80 (10.00%)
         occurrences all number
    3
    1
    9
    Back pain
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    7 / 80 (8.75%)
         occurrences all number
    4
    0
    11
    Osteoarthritis
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    7 / 80 (8.75%)
         occurrences all number
    3
    0
    8
    Muscle twitching
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 21 (4.76%)
    5 / 80 (6.25%)
         occurrences all number
    1
    1
    5
    Pain in extremity
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    2
    0
    5
    Infections and infestations
    COVID-19
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    40 / 80 (50.00%)
         occurrences all number
    1
    0
    47
    Influenza
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 21 (0.00%)
    8 / 80 (10.00%)
         occurrences all number
    3
    0
    11
    Nasopharyngitis
         subjects affected / exposed
    3 / 61 (4.92%)
    1 / 21 (4.76%)
    7 / 80 (8.75%)
         occurrences all number
    3
    1
    7
    Urinary tract infection
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    6 / 80 (7.50%)
         occurrences all number
    1
    0
    9
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    1
    0
    8
    Pneumonia
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    5 / 80 (6.25%)
         occurrences all number
    0
    0
    5
    Sinusitis
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    2
    0
    5
    Gastroenteritis viral
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    1
    0
    4
    Ear infection
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 21 (0.00%)
    4 / 80 (5.00%)
         occurrences all number
    0
    0
    4
    Metabolism and nutrition disorders
    Hypocalcaemia
         subjects affected / exposed
    5 / 61 (8.20%)
    9 / 21 (42.86%)
    15 / 80 (18.75%)
         occurrences all number
    7
    14
    29
    Hypercalcaemia
         subjects affected / exposed
    5 / 61 (8.20%)
    0 / 21 (0.00%)
    9 / 80 (11.25%)
         occurrences all number
    8
    0
    15

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    16 Mar 2021
    The protocol amendment was to address comments and recommendations from Health Authorities and provide clarification on the trial.
    10 Jun 2021
    The protocol amendment provided clarification on the trial and addressed a Health Authority comment.
    03 Aug 2021
    The protocol amendment updated the primary and secondary efficacy endpoints based on FDA recommendation.
    20 Dec 2021
    The protocol amendment updated the primary and secondary efficacy endpoints based on FDA recommendation.
    13 Dec 2022
    The protocol amendment added an efficacy endpoint for the open-label extension period and provided clarification on the trial.
    23 May 2023
    The protocol amendment addressed a Health Authority comment.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references
    http://www.ncbi.nlm.nih.gov/pubmed/36271471
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 22:14:00 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA